Navigation Links
Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
Date:5/6/2010

n cancer is one of the most common gynaecologic malignancies and the fifth most frequent cause of cancer death in women, with most of the cases occurring in women between 50 and 75 years of age. Overall, ovarian cancer accounts for 4% of all cancer diagnoses in women and 5% of all cancer deaths. Approximately 26,000 new cases and 17,000 deaths from this disease are estimated in the European community every year (Source: Gynaecologic Oncology 2004; 92:819-26). The National Cancer Institute estimates that in 2009, in the United States alone, there were 21,550 news cases of ovarian cancer and 14,600 related deaths.

About AEZS-108

AEZS-108 represents a new targeting concept in oncology using a cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors results in its accumulation and preferential uptake in the malignant tissue.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements invol
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... GLASGOW, Scotland , September 17, 2014 ... a new mode of action from a ... a decade  MGB Biopharma, a ... of anti-infectives, announces today that it has ... of its lead antibacterial, MGB-BP-3, against a ...
(Date:9/16/2014)... September 16, 2014 “Nature has developed, ... features that we desire in optical design,” said Joseph ... State University. “As we explore surfaces and structures at ... lessons were presented in San Diego in August during ... in Nature ” chaired by Shaw and Rongguang Liang ...
(Date:9/16/2014)... WASHINGTON, D.C., September 16, 2014 --The emerging field ... portable to the next level, enabling the construction ... highly efficient devices, individual molecules would take on ... and transistors. , A team of researchers from ... potential candidate for use in small-scale electronics: a ...
(Date:9/16/2014)... 16, 2014 Cardioxyl Pharmaceuticals, Inc. ... been shown to be effective in animal models following ... to intravenous infusions that could pave the way for ... presented yesterday at the Heart Failure Society of America,s ... Las Vegas . The research, ...
Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2
... Summary: Genmab Reports Results for the First Three Months of ... today results for the three month period ended March 31, ... revenues were DKK 167 million (approx. USD 36 million) for ... Genmab recognized,revenues of DKK 80 million (approx. USD 17 million)., ...
... Md., May 28 Novavax, Inc. (Nasdaq:,NVAX) a clinical-stage ... Chief Executive Officer, will be presenting at the,FBR Capital ... on,May 29, 2008 at The Grand Hyatt Hotel in ... company,s strategy, research and development progress. A,link to the ...
... NanoLogix, Inc. (Pink,Sheets: NNLX) a nano-biotechnology company ... personnel will showcase company technology at booth 1304 ... June 1-5 2008. The ASM,meeting is the world,s ... Dr. Sergey Gazenko and CEO Bret Barnhizer.,Exhibition information ...
Cached Biology Technology:Genmab Announces 2008 First Quarter Results 2Genmab Announces 2008 First Quarter Results 3Genmab Announces 2008 First Quarter Results 4NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update 2
(Date:9/17/2014)... on a Carnegie expedition in Australia,s Great Barrier Reef ... since the mid-1970s. The scientists suggest that ocean acidification ... slowdown. , In a quest for historical context ... current measurements of the growth rate of a section ... more than 30 years ago. Their work is published ...
(Date:9/17/2014)... of bacterial infections, including MRSA and MSSA could ... bumps that mimic the scaly surface of shark ... access journal Antimicrobial Resistance and Infection Control ... materials prevented the spread of human disease bacteria ... Sharklet, is an arrangement of ridges formulated to ...
(Date:9/16/2014)... Hopkins neuroscientists have discovered the "molecular brakes" that time ... cochleas of mice. These "hair cells" translate sound waves ... and are interpreted as sounds. If the arrangement of ... A summary of the research will be published in ... , "The proteins Hey1 and Hey2 act as brakes ...
Breaking Biology News(10 mins):Coral growth rate plummets in 30-year comparison 2Sharks' skin has teeth in the fight against hospital superbugs 2Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2
... URBANA A recent research study has shown that ... of food due to resource constraints, can lead to ... pregnancy. "Prior studies have shown that women ... experience health complications," said Craig Gundersen, a University of ...
... CORVALLIS, Ore. Scientists are a valuable and ... report, but too often do an inadequate job of ... a factual, non-technical, credible and neutral format. An ... establishment of "marine reserves" off the California coast offers ...
... 2010 - An article in the current issue of Global ... a perennial grass, could effectively reduce our dependence on fossil fuels, ... tool that models the future global climate, researchers predict that the ... natural vegetation will be paid back by Miscanthus within ...
Cached Biology News:Food insecurity increases risk of weight gain and complications during pregnancy 2Scientists need to be more proactive, effective at public communication 2Scientists need to be more proactive, effective at public communication 3
... is a personal desktop unit ideal for use ... , Rotation speed set at 12 rpm ... C , Bottle capacity of four 35 ... ml conical ,plastic bottles , Consistent, repeatable ...
... The SC250 Express is the latest edition ... SC250 Express has an extra large diameter ... The digital display panel allows precise setting ... Large chamber for handling large quantities and ...
... a no-frills, basic SpeedVac concentrator designed for ... this unit still features a standard Teflon ... of time and heat. It is designed ... a wide variety of different rotors for ...
... RC Maxi MB (for aqueous, other low ... evaporator systems respond to specific applications of ... safe concentration of heat-labile samples. The RC ... of cold traps and a wide selection ...
Biology Products: